FDA has approved InnoMed's Nasal-Aire II Petite for continuous positive airway pressure (CPAP) therapy for the treatment of obstructive sleep apnea in children aged older than 7 years or weighing more than 40 lbs.
FDA has approved InnoMed's Nasal-Aire II Petite for continuous positive airway pressure (CPAP) therapy for the treatment of obstructive sleep apnea in children aged older than 7 years or weighing more than 40 lbs. This product is the first to use a nasal prong/nasal cannula/nasal pillow design rather than the traditional over-the-nose mask, a change that is intended to lead to greater patient compliance.
This device was also approved to provide positive pressure-based noninvasive ventilation for pediatric patients in both acute care and home settings.
Pediatric cancer survivors and cardiovascular toxicity, disease risk
March 21st 2025Pediatric cancer survivors can be vulnerable to cardiovascular disease in the short- or long-term with increased recognition of cardiotoxic cancer treatments, as 5-year survival rates for children are greater than 85%.